Abstract |
A new immunomodulating agent, bestatin (INN: Ubenimex has low toxicity even after long-term oral administration and has significant modifications in immunological response. A cooperative randomized controlled study of bestatin immunotherapy in combination with remission maintenance chemotherapy for adult acute nonlymphocytic leukemia ( ANLL) was performed. After induction of complete remission, patients were randomized to the bestatin group (30 mg/bw per os (po) daily) and the control group. The 101 eligible cases ( bestatin: 48, control: 53) were analyzed; the bestatin group achieved longer remission than the control group and a statistically significant longer survival. Though this prolongation of remission was not significant in the bestatin group compared to the control group in the 15-49 yr age group, in the 50-65 yr age group it was significantly longer. Bestatin is shown to be a clinically useful drug for immunotherapy of adult ANLL, since it has prolonged survival and remission especially in elderly patients, with few side-effects.
|
Authors | K Ota, N Ogawa |
Journal | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
(Biomed Pharmacother)
Vol. 44
Issue 2
Pg. 93-101
( 1990)
ISSN: 0753-3322 [Print] France |
PMID | 2224060
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antibiotics, Antineoplastic
- Leucine
- ubenimex
|
Topics |
- Adolescent
- Adult
- Age Factors
- Aged
- Antibiotics, Antineoplastic
(therapeutic use)
- Drug Evaluation
- Female
- Follow-Up Studies
- Humans
- Leucine
(analogs & derivatives, therapeutic use)
- Leukemia, Myeloid, Acute
(drug therapy)
- Male
- Middle Aged
- Remission Induction
|